Muir-Torre syndrome (MTS) is a rare genetic disorder that combines features of an inherited tumor predisposition syndrome with abnormalities in the skin structure, particularly seborrheic keratoses and various types of adenomas. The condition belongs to a group of so-called inherited tumor-associated syndromes, in which the patient has an increased risk of developing malignancies such as colon cancer and kidney cancer. Patients with Muir-Torre syndrome have at least one of the following: skin lesions such as keratoses; the presence of adenomatous polyps in the intestine; and the occurrence of malignancies, especially in the digestive tract. To date, this disorder has been associated with abnormalities in the genes responsible for DNA repair, which causes a high predisposition to tumor growth.
History of the disease and interesting historical facts
Muir-Torre syndrome was first described in the mid-20th century. In 1974, William Muir and John Torre presented the results of their observations, in which they outlined the general phenomenon of a combination of skin diseases and malignant tumors in patients. Interestingly, individual cases of a similar clinical picture had been registered before that time, but their unification into a separate syndrome occurred relatively recently. Since then, numerous studies have been published in the medical literature on this syndrome, as well as compliance with the specification and recommendations for diagnosis and treatment. The syndrome was named after the two scientists, which emphasizes the important contribution to understanding its nature and pathogenesis.
Epidemiology
The epidemiology of Muir-Torre syndrome highlights its rarity: current statistics estimate that the syndrome occurs in approximately 1 in 2% patients with hereditary cancer. The incidence varies across populations and regions, with an overall estimated incidence of 1 in 100,000. Given that the syndrome is associated with a high predisposition to malignancies, particularly in young people, it is important to diagnose and monitor these patients early. The prevalence of the syndrome highlights the need for genetic testing in families with hereditary cancers.
Genetic predisposition to this disease
Genetic predisposition to Muir-Torre syndrome is associated with mutations in certain genes that are responsible for the DNA repair mechanism. This includes genes such as MLH1 and MSH2, which play a key role in correcting errors that occur during DNA replication. When they are disrupted, the likelihood of mutation accumulation increases, which leads to disruption of cellular control and, as a result, to the development of tumors. Current research suggests that it is this genetic background, combined with environmental factors, that may be the cause of the development of both skin manifestations and internal cancer processes in patients. Genetic counseling is becoming relevant for family members with a known history of the disease.
Risk factors for the development of this disease
Risk factors that contribute to the development of Muir-Torre syndrome can be both physical and chemical. These include:
- Heredity: Having close relatives with cancer or Muir-Torre syndrome increases the risk.
- Smoking: Smoking has been shown to be a significant risk factor for developing various forms of cancer.
- Exposure to chemical carcinogens: Working in conditions where you are exposed to certain chemicals can also increase the likelihood of developing pathologies.
- Ultraviolet radiation. Excessive sun exposure can trigger skin manifestations in people with a genetic predisposition.
- Effects of viruses: Some viral infections, such as HPV (human papillomavirus), may be associated with an increased risk of developing skin and internal tumors.
Diagnosis of this disease
Diagnosis of Muir-Torre syndrome involves several steps and methods based on symptoms and family history:
- Main symptoms: Patients may exhibit skin changes such as keratoses and tumors and have a family history of malignancy.
- Laboratory tests: Genetic testing can identify mutations in known genes associated with the syndrome.
- Radiological examinations: CT and MRI scans can help identify internal tumors, especially in the digestive tract and kidneys.
- Other types of diagnostics: Biopsy of altered areas of skin, as well as colonoscopy to detect polyps in the intestine.
- Differential diagnosis: It is important to exclude other syndromes associated with a genetic predisposition to tumors, such as Li-Fraumeni syndrome.
Treatment
Treatment for Muir-Torre syndrome is multifaceted and depends on the clinical manifestations. Common treatment approaches include:
- General treatment: Regular monitoring of patients with genetic testing and cancer screening.
- Pharmacological treatment: The use of anticancer drugs, such as chemotherapy, may be required depending on the type and stage of cancer.
- Surgical treatment. Removal of tumors and polyps, especially if they cause disease or have a high risk of degeneration.
- Other treatments: Immunotherapy and supportive therapy may be used depending on the characteristics of the tumors.
List of medications used to treat this disease
The following medications may be used to treat Muir-Torre syndrome:
- Fluorouracil
- Cisplatin
- Calcium folinate
- Doxorubicin
- Irinotecan
Disease monitoring
Monitoring of patients with Muir-Torre syndrome includes:
- Control stages. Regular check-ups and examinations for early detection of tumors.
- Prognosis: With early diagnosis and adequate treatment, the chances of survival are significantly increased.
- Complications. Complications associated with tumor progression and metastasis are possible.
Age-related features of the disease
Muir-Torre syndrome can present in different age groups. Children and adolescents may have more severe symptoms, while older adults are more likely to have malignancies associated with the syndrome. This highlights the importance of monitoring for all age groups, as the clinical presentation can vary and symptoms can often be missed if diagnosis is delayed.
Questions and Answers
- What is Muir-Torre syndrome? It is a genetic disorder that combines skin manifestations with an increased risk of malignant tumors.
- What are the main symptoms of the syndrome? The main symptoms include skin keratoses and the presence of adenomatous polyps in the intestine.
- What is the genetic predisposition to the syndrome? Muir-Torre syndrome is associated with mutations in the MLH1 and MSH2 genes.
- How is this syndrome diagnosed? Diagnosis includes genetic testing, laboratory tests and radiological examinations.
- What is the treatment for Muir-Torre syndrome? Treatment may include surgery, chemotherapy, and regular monitoring of the patient's condition.
